Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin.

Trial Profile

Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2012

At a glance

  • Drugs Peginterferon alfa (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms POMOSCH
  • Sponsors Schering-Plough
  • Most Recent Events

    • 10 Jan 2012 Actual patient number (790) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Planned end date changed from Mar 2011 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top